The U.S. Food and Drug Administration has approved Gadavist (gadobutrol), a contrast agent for use in patients undergoing magnetic resonance imaging (MRI) of the central nervous system. Read…
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.



